India’s Bioeconomy

Context: India’s bioeconomy touched $166 billion in 2024, up from $10 billion in 2014, as announced by Union Minister while inaugurating a BSL-4 biocontainment facility in Gujarat.

About India’s Bioeconomy:

What it is?

• India’s bioeconomy refers to the economic value generated from biotechnology, biopharma, agriculture biotech, bio-industrial products, bio-energy, and health sciences.

Key facts & data:

• India’s bioeconomy has achieved a remarkable 16-fold growth over the last decade, surging from $10 billion in 2014 to $165.7 billion by 2026.

• As of 2026, the market is distributed across four critical segments:

• Bio-Industrial (47%): The largest share, led by the Ethanol Blending Program which achieved its 20% (E20) target in 2025, five years ahead of schedule. Bio-Pharma (35%): India remains the “Pharmacy of the World,” supplying 65% of the WHO’s vaccine requirements. Bio-Research & IT (9%): The fastest-growing segment, fuelled by AI-driven drug discovery. Bio-Agri (8%): Cantered on climate-resilient crops and bio-fertilizers.

• Bio-Industrial (47%): The largest share, led by the Ethanol Blending Program which achieved its 20% (E20) target in 2025, five years ahead of schedule.

• Bio-Pharma (35%): India remains the “Pharmacy of the World,” supplying 65% of the WHO’s vaccine requirements.

• Bio-Research & IT (9%): The fastest-growing segment, fuelled by AI-driven drug discovery.

• Bio-Agri (8%): Cantered on climate-resilient crops and bio-fertilizers.

• The number of biotech start-ups has skyrocketed from 50 in 2014 to over 11,000 in 2026.

• In addition to the NIV in Pune, 2026 marks the operationalization of state-led BSL-4 Bio-Containment facilities (such as the one in Gujarat).

Relevance for UPSC Examination:

• GS Paper II (Governance & Health): Biotech and BSL-4 labs strengthen public health preparedness, pandemic surveillance, and the One Health approach.

• Biotech and BSL-4 labs strengthen public health preparedness, pandemic surveillance, and the One Health approach.

• GS Paper III (Science, Technology & Economy): The bioeconomy links biotechnology, startups, and biomanufacturing with growth, while biosafety manages risks.

• The bioeconomy links biotechnology, startups, and biomanufacturing with growth, while biosafety manages risks.

• GS Paper IV (Ethics & Public Policy): Life-science research requires ethical conduct, bio-safety, and control of antimicrobial resistance.

• Life-science research requires ethical conduct, bio-safety, and control of antimicrobial resistance.